Who we are
VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies.
Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.
Our Programmes
Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss.
Who we are
VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies.
Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.
Our Programmes
Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss.
The VasoDynamics Pipeline
The company’s technology is currently differentiated in three formulation platforms with several product pipelines for the protection of
skin, mucosa and hair for various types of cancer patients.
The VasoDynamics Pipeline
The company’s technology is currently differentiated in three formulation platforms with several product pipelines for the protection of
skin, mucosa and hair for various types of cancer patients.
Our Latest News:
UK MHRA Scientific Advice on Pivotal Trial of NG13-2, a Novel Product for the Prevention of Chemotherapy-Induced Alopecia
VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, is pleased to announce that the company has received the notification of the Date for Scientific Advisory meeting from the MHRA on the NG13-2 programme for the prevention of chemotherapy-induced alopecia.